Latest Product Development News

Wide Open Agriculture Ltd has announced a Share Purchase Plan aiming to raise up to $500,000 through the issue of new shares and free-attaching options, pending shareholder approval. This capital raise complements a recent $2.6 million placement to support the company’s growth and production ramp-up.

IDP Education has revised its FY25 guidance, forecasting a sharp decline in student placements and language testing volumes due to persistent immigration policy uncertainty across key markets including the UK, Australia, Canada, and the US.

Bio-Gene Technology Limited has raised $338,500 through a Share Purchase Plan, contributing to a total capital raise of $2.45 million to advance its bio-insecticide products.

Hydralyte USA reports its best EBITDA performance since IPO, driven by strong sales and cost reductions, setting the stage for growth with upcoming product launches.

Singular Health Group has completed a $773,000 placement with Marin and Sons, alongside exercising options and issuing shares under its employee incentive plan, strengthening its capital base.

Papyrus Australia has secured a pivotal contract with UniSA to establish a Rapid Prototyping and R&D facility, advancing its sustainable packaging technology and commercial production plans.

Cardiex Digital Vascular Biomarkers announces a A$6.5 million equity raise to fund inventory, marketing, product development, and debt repayment, aiming to solidify its position in the expanding cardiovascular health market.

dorsaVi has secured a three-year agreement with SANO Health to deploy its ViSafe+ wearable sensor technology across remote mining sites, reinforcing its foothold in high-risk occupational health sectors.

Beamtree Holdings has forged a strategic alliance with the NHS Confederation to launch a pioneering healthcare analytics platform across UK NHS Trusts, marking a significant step in its international expansion.

Nanollose Limited has appointed Andrew Moullin as its new CEO and Managing Director, aiming to leverage his extensive commercial expertise to fast-track the company’s microbial cellulose technology towards market readiness.

Aspermont Limited reports steady subscription growth with $11.2 million in annual recurring revenue despite a dip in total revenue, while gearing up for new data product launches and an IPO.

Pacific Edge Limited has launched a NZ$20 million capital raise to bolster its cash reserves amid the loss of Medicare coverage for its bladder cancer diagnostic tests, aiming to accelerate US market adoption and support new product development.